We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.00 | -3.23% | 30.00 | 29.00 | 31.00 | 31.00 | 30.00 | 31.00 | 186,607 | 10:15:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Services, Nec | 3.4M | -46.22M | -0.4626 | -0.65 | 29.98M |
TIDMRENX
RNS Number : 1932L
Renalytix AI PLC
20 December 2018
Renalytix AI plc
("RenalytixAI" or the "Company")
Director/ PDMR Shareholding
The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of 112 pence per share.
Following this purchase, Mr Mills is interested in 9,199,568 Ordinary Shares representing 17.09% of the total voting rights in the Company.
Enquiries:
Renalytix AI plc www.renalytixai.com James McCullough, CEO Via Walbrook PR or Tel: +1 646 397 3970 --------------------------------------------------- N+1 Singer (Nominated Adviser & Broker) Tel: 020 7496 3000 ----------------------------------------------- Aubrey Powell / James White / George Tzimas (Corporate Finance) ----------------------------------------------- Tom Salvesen / Mia Gardner (Corporate Broking) ----------------------------------------------- Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com ----------------------------------------------------- Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303 -------------------------------------------------
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Harwood Capital LLP (Harwood) as investment manager to North Atlantic Smaller Companies Investment Trust plc and Oryx ------------------------------------ --------------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------------------- a) Position/status Christopher Mills, non-exec director of the issuer and director of NASCIT and Oryx International Growth Fund Ltd ------------------------------------ --------------------------------------------- b) Initial notification Initial Notification /Amendment ------------------------------------ --------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------------- a) Name Renalytix AI plc ------------------------------------ --------------------------------------------- b) LEI 213800NTOH3FK3WER551 ------------------------------------ --------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------------- a) Description of the Ordinary shares of 0.25 pence each financial instrument, type of instrument Identification code GB00BYWL4Y04 b) Nature of the transaction Share purchase ------------------------------------ --------------------------------------------- c) Price(s) and volume(s) ------------------------ ---------------- Price(s) Volume(s) ------------------------ ---------------- 112.00 pence 3,168 ------------------------------------------------------------------ ---------------- d) Aggregated information - Aggregated volume 3,168 - Price GBP3,548.16 e) Date of the transaction 20 December 2018 ------------------------------------ --------------------------------------------- f) Place of the transaction London Stock Exchange ------------------------------------ ---------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHFKKDDOBDDFBB
(END) Dow Jones Newswires
December 20, 2018 12:20 ET (17:20 GMT)
1 Year Renalytix Chart |
1 Month Renalytix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions